Oligometastatic Mesothelioma Treated with Ablative Radiotherapy (OMAR): A Multicenter Study
Cancers · 27.08.2025 · 17 (17) · 2797
DOI: 10.3390/cancers17172797 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 27.08.2025. Verfasst von Davide Franceschini und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy and Radiosurgery, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondazione Oxiamo ONLUS.
Abstract (Originalsprache)
Background/Objectives: This multicenter retrospective study aims to evaluate the role of Ablative Radiotherapy (RT) in patients with unresectable pleural mesothelioma (PM) who experienced radiological progression after at least one line of chemotherapy, with a maximum involvement of three pleural or extrapleural sites.
Methods
Adult patients (≥18 years) with PM treated with stereotactic radiotherapy between 2011 and 2022, limited to a maximum of three pleural or extrapleural sites, were included in the analysis. Ablative RT was required to be administered with radical intent. Endpoints were time to further systemic therapy (TFST), local control (LC), progression-free survival (PFS), overall survival (OS), and acute and late radiotherapy-related toxicity.
Results
A total of 56 patients were identified from six Italian and one Swiss radiotherapy center. Treatment was generally well tolerated. Ten patients experienced grade 1 or 2 acute toxicity, while four patients reported persistent chest pain, with one case reaching grade 3 as late toxicity. The median TFST was 18.6 months, with TFST rates of 61.7% and 46.4% at 12 and 24 months, respectively. The median OS was 37.63 months, with 1- and 2-year OS rates of 85.2% and 65.6%. Local control was favorable (79% at 1 year), but most patients experienced disease recurrence outside the SABR treatment volume. The median disease progression-free survival (DPFS) was 8.17 months, with 1- and 2-year DPFS rates of 36% and 19%, respectively. Smoking history correlated with OS and DPFS in univariate analysis, while statistical significance for OS was maintained in multivariate analysis. Additionally, nodal status and PTV volume were associated with OS.
Conclusion
SABR is a safe and effective approach for the treatment of oligorecurrent/oligoprogressive PM. The time to further systemic therapy was extended up to 18 months. At two years, 10% of patients remained disease-free, and more than half were alive at three years, suggesting a potentially indolent biological behavior in oligometastatic PM.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiotherapy and Radiosurgery, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy.
- Department of Radiotherapy, Cliniche Humanitas Gavazzeni, via Gavazzeni 21, 24125 Bergamo, Italy.
- Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Rämistrasse 100, 8091 Zurich, Switzerland.
- Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, 37034 Negrar Di Valpolicella, Italy.
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.
- Division of Radiotherapy, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy.
ORCID-Profile: Davide Franceschini, Luca Nicosia, Gaia Piperno, Matteo Sepulcri, Antonio Marco Marzo, Marco Krengli, Barbara A Jereczek-Fossa, Filippo Alongi, Giovanni Luca Ceresoli, Paolo Borghetti, Marta Scorsetti
Förderung
- Fondazione Oxiamo ONLUS
Zitieren
APA
Franceschini, D., Ghirardelli, P., Frrokaj, P., Andratschke, N. H., Nicosia, L., Parisi, E., Piperno, G., Sepulcri, M., Alì, E., Marzo, A. M., Bendoni, S., Spoto, R., Krengli, M., Ciammella, P., Jereczek-Fossa, B. A., Romeo, A., Mazzola, R., Alongi, F., Guckenberger, M., …, & Scorsetti, M. (2025). Oligometastatic Mesothelioma Treated with Ablative Radiotherapy (OMAR): A Multicenter Study. Cancers, 17(17), 2797. https://doi.org/10.3390/cancers17172797
Vancouver
Franceschini D, Ghirardelli P, Frrokaj P, Andratschke NH, Nicosia L, Parisi E, et al. Oligometastatic Mesothelioma Treated with Ablative Radiotherapy (OMAR): A Multicenter Study. Cancers. 2025;17(17):2797. doi:10.3390/cancers17172797
BibTeX
@article{Franceschini2025,
author = {Franceschini, Davide and Ghirardelli, Paolo and Frrokaj, Patricia and Andratschke, Nicolaus H and Nicosia, Luca and Parisi, Elisabetta and Piperno, Gaia and Sepulcri, Matteo and Alì, Emanuele and Marzo, Antonio Marco and Bendoni, Stefano and Spoto, Ruggero and Krengli, Marco and Ciammella, Patrizia and Jereczek-Fossa, Barbara A and Romeo, Antonino and Mazzola, Rosario and Alongi, Filippo and Guckenberger, Matthias and Ceresoli, Giovanni Luca and Loi, Mauro and Borghetti, Paolo and Scorsetti, Marta},
title = {Oligometastatic Mesothelioma Treated with Ablative Radiotherapy (OMAR): A Multicenter Study},
journal = {Cancers},
year = {2025},
volume = {17},
number = {17},
pages = {2797},
doi = {10.3390/cancers17172797}
}
EUVIMED